1303571-92-7

Upstream product

• 1679-18-1 4-Chlorophenylboronic acid 
• 5367-28-2 5-chloro-2-nitrotoluene 
• 1303576-81-9 methyl 5-(4-chlorophenyl)-1-hydroxy-1H-indole-2-carboxylate 
• 1303575-18-9 C₁₆H₁₂ClNO₅ 
• 1303573-50-3 4'-chloro-3-methyl-4-nitrobiphenyl 

Relevant academic research and scientific papers

LDH inhibitors as treatment for fibrosis and fibrotic-related disorders

One aspect of the disclosure relates to methods of treating a fibrotic condition in an individual. The methods include administering to an individual having a fibrotic condition an effective amount of a lactic dehydrogenase (LDH) inhibitor, wherein the fibrotic condition involves an internal organ or tissue, or ocular tissue, and said administering is effective to treat the fibrotic condition. Methods of administration and pharmaceutical compositions and systems for practicing such methods are also disclosed.

N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation

Current cancer research is being increasingly focused on the study of distinctive characters of tumour metabolism, resulting in a switch from oxidative phosphorylation to glycolysis (Warburg effect). Isoform 5 of human lactate dehydrogenase (hLDH5), which

COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS

The present invention concerns compounds, some of which are novel, and their pharmaceutical applications. The compounds of the invention inhibit the enzyme lactate dehydrogenase (LDH) involved both in the metabolic process of hypoxic tumour cells, and in the process used by parasitic protozoa that cause malaria to obtain most of the energy they need.